



ABN 82 010 975 612

Level 18, 101 Collins Street
Victoria 3000 Australia
Telephone: + 61 7 3273 9133
Facsimile: + 61 7 3375 1168
www.tbgbio.com

18 March 2020

ASX Announcement

CE Mark approval of COVID-19 Virus Diagnostic Kit

TBG Diagnostics Limited ("Company") announces that its investee company TBG Biotechnology Xiamen Inc. ("TBG Xiamen"), a China based molecular diagnostics company, has received the CE Mark approval for its COVID-19 Nucleic Acid Diagnostics Kit.

CE Mark certification indicates that the COVID-19 Nucleic Acid Diagnostics Kit meets the essential health, safety, and environmental protection requirements of the applicable European regulations to allow the sale of the kit throughout the European Economic Area.

This RNA based diagnostic kit uses real time PCR technology platform with 3 color labeling to detect distinctive segments within RDRP, N and E genes of the SARS-CoV-2 virus.

This approval enables the test to be sold as an in vitro diagnostic (IVD) for the diagnosis of SARS-CoV-2 (COVID-19) in all regions that accepts CE marking. TBG Xiamen's kit will be available for immediate validation and purchase.

The Company has a 46.65% ownership interest in TBG Xiamen.

A handwritten signature in blue ink, appearing to read 'Jitto Arulampalam'.

Jitto Arulampalam
+61 421 617 766
Executive Chairman
On behalf of the Board of Directors
TBG Diagnostics Limited